Guardant Health Reports $982 Million Revenue for Fiscal Year 2025, Despite $416.3 Million Net Loss

Guardant Health, Inc. reported total revenue of $982 million for the fiscal year ended December 31, 2025, a 33% increase compared to the $739 million reported for the previous year. The growth was primarily driven by a 26% increase in oncology revenue, reaching $683.6 million, attributed to a rise in test volume to approximately 276,000. Biopharma and data revenue also contributed, increasing by 18% to $210.1 million, fueled by the GuardantINFINITY test and companion diagnostic development services. Screening revenue, which includes the Shield blood test, reached $79.7 million, while licensing and other revenue decreased by 37% to $8.6 million due to nonrecurring milestone revenue in the prior year.

Despite the revenue growth, Guardant Health reported a net loss of $416.3 million for 2025, slightly lower than the $436.4 million loss in 2024. The cost of revenue increased by 20% to $349 million, driven by higher sample volumes, but partially offset by reduced cost per sample for certain tests. Operating expenses also increased, with research and development expenses rising by 5% to $364.2 million, primarily due to personnel and material costs. Sales and marketing expenses saw a significant increase of 36% to $494.7 million, reflecting commercial team expansion and marketing activities. General and administrative expenses increased by 17% to $211.4 million, driven by higher stock-based compensation and information technology costs.

Key operational developments included the FDA approval and commercial launch of the Shield blood test for colorectal cancer screening, as well as Medicare coverage for the test. The company also expanded its Guardant Reveal test to include late-stage therapy response monitoring. International expansion continued with the establishment of a liquid biopsy testing service at Policlinico Gemelli in Italy. The company's workforce as of December 31, 2025, stood at 2,506 employees, with a focus on maintaining a diverse and inclusive work environment.

Looking ahead, Guardant Health anticipates continued investment in research and development, particularly in clinical studies, to drive innovation and secure favorable coverage decisions. The company also expects to increase its sales and marketing efforts to support product adoption and expand its international presence. While the company believes its current cash reserves are sufficient to meet its anticipated cash requirements for the next 12 months, it may consider raising additional capital in the future to fund its growth initiatives. The company's financial performance remains subject to various factors, including payer coverage and reimbursement rates, competition, and regulatory changes.